The Top 5 Biosimilar Articles for the Week of June 26

Hi, I’m Justina Petrullo for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of June 26th, 2023.

Number 5: Enhancing pharmacists’ knowledge of biosimilars can assist in promoting their use and defeat misconceptions and misinformation related to generic drugs and biosimilars.

Number 4: Researchers of a retrospective cohort study find that a rituximab biosimilar, BCD-020, was safe and effective in pediatric patients with lupus nephritis.

Number 3: The ranibizumab biosimilar XSB-001 (Ximluci) demonstrates biosimilarity to the originator (Lucentis) in a phase 3 trial in neovascular age-related macular degeneration (nAMD).

Number 2: An analysis of 25 studies finds adalimumab, infliximab, and etanercept biosimilars just as safe, effective, and tolerable in comparison with their originators in the treatment of rheumatoid arthritis.

Number 1: In his latest column, Sarfaraz K. Niazi, PhD, takes a look at common misconceptions about biosimilar development and expresses how companies can seize new opportunities to save the US biosimilar market and generate profit.

To read all of these articles and more, visit centerforbiosimilars.com.